SEC Form 4 · accession 0001385508-18-000104
OPIANT PHARMACEUTICALS, INC. · OPNT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Phil Skolnick
Officer — Chief Scientific Officer
Period of report
Nov 1, 2018
Accepted (ET)
Nov 5, 2018 · 4:41 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001385508
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 1, 2018 | M | 5,038 | $9.00 | A | 5,038 | D | |
| Common Stock | Nov 1, 2018 | S | 1,521 | $18.14 | D | 3,517 | D | |
| Common StockF3 | Nov 5, 2018 | S | 300 | $17.33 | D | 3,217 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F4 | $9.00 | Nov 1, 2018 | M | 10,000 | D | Aug 6, 2018 | Feb 6, 2027 | Common Stock | 5,038 | 180,000 | D |
Explanation of responses
- F1The option was exercised pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.
- F2The shares were sold pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.
- F3This transaction was executed in multiple trades at prices ranging from $17.75 to $17.76. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4Pursuant to the Stock Option Agreement, the number of shares issued on a cashless basis is determined by the following formula: Number of shares = (number of options times (prior day stock price less exercise price)) divided by the prior day stock price.